UNSPSC 51422316: Prednylidene

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IF8PQP966U, chemically known as 11beta,17,21-trihydroxy-16-methylenepregna-1,4-diene-3,20-dione but generally known as prednylidene, which bears US NIH Compound Identifier 11740. European Medicines Agency schedules Prednylidene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10021MIG.

UNSPSC 51422316 Prednylidene is a Commodity code that captures pharmaceutical products and related health-supply procurement by state and local bodies, though recent activity under this specific code shows limited direct relevance. The two recent opportunities tagged to this code diverge significantly from the code's nominal pharmaceutical scope: Seminole County, Florida is procuring naloxone and drug deactivation systems through an IFB (due Jul 26, 2023), and the Texas Health and Human Services Commission issued an RFI on Apr 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs. The issuing bodies span county health departments and state health agencies, suggesting that when the code does surface in state and local procurement, it reaches both municipal and state-level buyers managing pharmaceutical supply chains and emergency health response capabilities.

Geographic activity under this code appears concentrated in the South, with recent postings from Florida and Texas, though the sample size is too small to characterize broader regional patterns. The Seminole County opportunity is a straightforward competitive bid for 1,900 annual units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, fixed-fee pricing, a two-year initial term with one-year renewal option, and standard compliance requirements including E-Verify and drug-free workplace certification. The Texas RFI, by contrast, is exploratory market intelligence gathering rather than a formal competitive solicitation, designed to inform future procurement strategy around direct-to-manufacturer relationships and pharmacy benefit management. Neither opportunity specifies set-asides for disadvantaged enterprises, and the small recent-opportunity sample suggests limited current procurement velocity under this code.